An Actionable Mutation Profiling Multicenter study of Patients with Newly Diagnosed Acute Myeloid Leukemia Unfit for the First Standard Treatment or relapse/refractory Acute Myeloid Leukemia

Conditions

acute myeloid leukemia

Naoko Hosono, Takahiro Yamauchi, SungGi Chi, Kentaro Fukushima, Hirohiko Shibayama et al. (30 authors)

Blood2021-11-054 citations

10.1182/blood-2021-149960

Clinical Significance of FLT3 Mutations in a Comprehensive NGS Multicenter Study of AML: HM-Screen-Japan 01

Kentaro Fukushima, Hirohiko Shibayama, SungGi Chi, Naoko Hosono, Takahiro Yamauchi et al. (31 authors)

Blood2021-11-051 citations

10.1182/blood-2021-146796

Genomic Analysis Focusing on RUNX1-RUNX1T1 in Japanese Patients with AML: HM-Screen-Japan 01

Seiichiro Katagiri, Daigo Akahane, Akihiko Gotoh, SungGi Chi, Kentaro Fukushima et al. (30 authors)

Blood2021-11-051 citations

10.1182/blood-2021-148492

Properties and Distribution of IDH-1/2 Mutations in Acute Myeloid Leukemia By the Comprehensive Genomic Analysis

Satoshi Uchiyama, Hirotaka Nakamura, SungGi Chi, Kentaro Fukushima, Hirohiko Shibayama et al. (31 authors)

Blood2021-11-05

10.1182/blood-2021-149801

Genomic Analysis of NPM1 Mutation and KMT2A(MLL)-Rearrangement/Amplification in Japanese Patients with Acute Myeloid Leukemia: Hematologic Malignancies (HM)-Screen-Japan 01

SungGi Chi, Kentaro Fukushima, Hirohiko Shibayama, Naoko Hosono, Takahiro Yamauchi et al. (36 authors)

Blood2021-11-05

10.1182/blood-2021-149425

Interim Analysis of Hematologic Malignancies (HM)-Screen-Japan 01: A Mutation Profiling Multicenter Study of Patients with AML

Ken‐ichi Miyamoto, Kentaro Fukushima, SungGi Chi, Hirohiko Shibayama, Naoko Hosono et al. (28 authors)

Blood2020-11-052 citations

10.1182/blood-2020-139147

Genetic Features of AML with MLL-Rearrangement and NPM1 Mutation: An Interim-Analysis of HM-Screen-Japan 01

SungGi Chi, Naoko Hosono, Takahiro Yamauchi, Kentaro Fukushima, Hirohiko Shibayama et al. (37 authors)

Blood2020-11-05

10.1182/blood-2020-139240

Genomic Analysis of FLT3 Mutations in a Comprehensive NGS Multicenter Study of AML: HM-Screen-Japan 01

Kentaro Fukushima, SungGi Chi, Hirohiko Shibayama, Naoko Hosono, Takahiro Yamauchi et al. (28 authors)

Blood2020-11-04

10.1182/blood-2020-137343

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Pathologically proven acute myeloid leukemia. 2) Any of the following requirements is satisfied. i) Patient with newly diagnosed acute myeloid leukemia unfit for the first standard treatment ii) Patient with relapse or refractory acute myeloid leukemia. 3) Sufficient sample is collected by bone marrow aspiration 4) Age at registration is of 20 years or older. 5) Witten informed consent is taken.

Exclusion criteria

Exclusion criteria: 1) Patient is judged by the investigator to be inappropriate for study participation for any reason. 2) Pathologically proven granulocytic sarcoma.

Design outcomes

Primary

Measure	Time frame
Frequency or characteristics of cancer genome alteration	—

Secondary

Measure	Time frame
Association between each cancer genome alterations and clinicopathological characteristics or prognosis, Quality of the specimen contributing to gene analysis	—

Countries

Japan

Contacts

Public ContactKenichi Miyamoto

National Cancer Center Hospital East Department of Hematology

kenmiyam@east.ncc.go.jp0471331111

Outcome results